Studio di efficacia e sicurezza del dovramilasto nelle persone con lebbra di tipo 2
Uno studio di sicurezza e di efficacia a dose controllata da 12 settimane, emergente, randomizzato, standard di cure controllato, di efficacia nelle persone con lebbra 2 di tipo 2 da moderata a grave.
Dovramilast has not been approved for leprosy type 2 reaction (erythema nodosum leprosum, ENL) or any other disease anywhere in the world. In this study, an experimental drug called dovramilast is being tested to see how it compares to current treatments for leprosy type 2 reaction. Specifically, this study aims to assess the efficacy of 100mg or 150 mg dovramilast compared with standard treatments (also known as standard of care). This study also aims to assess the safety of two strengths in adults with leprosy type 2 reaction.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Abomey-Calavi, Benin
- Non ancora reclutamento
- Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
-
-
-
-
-
Divo, Côte d'Ivoire
- Non ancora reclutamento
- Chr de Divo
-
-
-
-
-
Manila, Filippine
- Reclutamento
- Philippine General Hospital, University of the Philippines, Manila
-
Contatto:
- Dofitas
- Numero di telefono: 63285548400
- Email: bldofitas@up.edu.ph
-
-
-
-
-
Yogyakarta, Indonesia
- Reclutamento
- Universitas Gadjah Mada
-
Contatto:
- Shinta Trilaksmi Dewi, MD, PhD
- Numero di telefono: +6282137381045
- Email: shinta.trilaksmi.d@ugm.ac.id
-
-
-
-
-
Tôlanaro, Madagascar
- Reclutamento
- Programme national lutte contre la lèpre
-
Contatto:
- Andrinamira Randrianantoandro, MD
- Numero di telefono: +261 340600115
- Email: andriamiradomoina@gmail.com
-
-
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98104
- Reclutamento
- Harborview Medical Center, University of Washington
-
Contatto:
- Dr Jason Simmons, MD, PhD
- Numero di telefono: 206-744-5463
- Email: jasonds@uw.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Aged 18 years of age or older.
-
Provision of written informed consent.
-
Laboratory confirmed previous or current Mycobacterium leprae or Mycobacterium lepromatosis infection.
-
Leprosy type 2 reaction meeting the following criteria:
-
Either:
i. Acute (first episode and no treatment initiated) or ii. Recurrent (at least one further episode occurring 28 days or more after withdrawal of leprosy type 2 reaction treatment).
-
Presence of at least 10 leprosy type 2 reaction tender papular and/or nodular skin lesions (not including scars).
-
An ENLIST score of at least 9.
-
-
If a woman of reproductive potential, agree to the use of two reliable contraceptive measures (at least one of which is a highly effective form of contraception) from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care. Refer to Special Considerations for additional information.
-
If male (including those who have had a successful vasectomy), agree to using a latex condom during any sexual contact with women of reproductive potential from Screening until at least 4 weeks after completion of treatment with dovramilast or standard of care.
Exclusion Criteria:
-
Chronic leprosy type 2 reaction, defined as the reaction occurring for 24 weeks or more during which a subject has required treatment either continuously or where any treatment free period had been < 28 days.
-
Receipt of thalidomide, lenalidomide, pomalidomide, systemic corticosteroids, clofazimine (> 50 mg/day), apremilast or any other phosphodiesterase (PDE) 4 inhibitor, or immunosuppressive/immunomodulatory treatment within 28 days of Baseline.
-
Receipt of an investigational agent within 28 days of Baseline or 5 half-lives of the investigational agent (whichever is longer).
-
Leprosy type 2 reaction with orchitis, uveitis, iritis, or severe neuritis (Grade 3 or greater severe neuritis).
-
Current diagnosis of leprosy type 1 reaction or Lucio's phenomenon.
-
Current tuberculosis, malaria, cutaneous or visceral leishmaniasis or other serious bacterial, viral, or parasitic infection at Screening or Baseline.
-
Active systemic fungal infection requiring or undergoing treatment.
-
Other than leprosy type 2 reaction, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
-
Other than leprosy type 2 reaction, any other dermatological condition that could, in the opinion of the Investigator, interfere with the study assessments.
-
Chronic hepatitis B, chronic hepatitis C, or human immunodeficiency virus (HIV) positive.
-
Pregnant women or breastfeeding mothers.
-
Use (or planned use) of antimetabolites or alkylating agents, rifampin use more frequent than monthly, phenobarbital, carbamazepine, phenytoin, traditional or herbal preparations (including St. John's wort), foods (including grapefruit) known to affect activity of the cytochrome (CYP)3A4 enzyme; of all strong CYP3A and P-gp inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, ritonavir, cobicistat, diltiazem; and sensitive substrates of CYP3A4, CYP2C9, CYP2C19, and P-gp. Other CYP3A4, CYP2C9, CYP2C19, and P-gp non-sensitive substrates should be used with caution when concomitantly administered with dovramilast.
-
Known or suspected active substance abuse or a history of substance abuse within 6 months prior to Screening.
-
Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or Randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
-
Current diagnosis of depression, and/or history of suicide ideation
-
History of or presence of cardiac disease, including:
- Clinically significant abnormal electrocardiogram
- QTcF > 450 msec
-
Receipt of a vaccination within 7 days of Baseline.
-
Known or suspected hypersensitivity to: PDE4 inhibitors including dovramilast or apremilast; thalidomide; prednisolone, or; excipients used in the formulation of dovramilast, thalidomide or prednisolone.
-
Body Mass Index < 15 kg/m^2 or > 35 kg/m^2.
-
Unable to, or significant difficulty with, swallowing tablets/capsules.
-
Anemia requiring transfusion.
-
History of or current pancreatitis.
-
Known or suspected cirrhosis of the liver.
-
The following laboratory abnormalities:
- White blood cells (WBC) < 2.5 x 10^9/ L.
- Neutrophils (granulocytes) < 1.0 x 10^9/L.
- Platelets < 80 x 10^9/L.
- Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of reference range.
- Albumin < 30 mg/dL.
- Bilirubin > 2 mg/dL
- Calculated creatinine clearance (Cockcroft Gault) < 50 milliliter (mL)/minute.
- Lipase ≥ 1.6 times the upper limit
-
Previous participation in this study
-
Unwilling, unlikely or unable to comply with all protocol specified assessments, including photographic assessments
-
Enrolled in another leprosy type 2 reaction treatment study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Dovramilast 100 mg
|
Dovramilast |
|
Sperimentale: Dovramilast 150 mg
|
Dovramilast |
|
Comparatore attivo: Standard of care
Prednisolone (or thalidomide US sites only) |
Standard of care Standard of care (US only) |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The proportion of dovramilast (100 mg or 150 mg) recipients achieving a 75% improvement in leprosy type 2 reaction skin lesions at week 12
Lasso di tempo: 12 weeks
|
The proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count of at least 75% from Baseline at Week 12 without the need for rescue. Rescue is defined as:
|
12 weeks
|
|
Incidence and severity of adverse events
Lasso di tempo: 12 weeks
|
The incidence and severity of adverse events, changes in vital signs and blood dyscrasias |
12 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Modifica dal punteggio di severità Studio di gravità del basale dell'arruola (Eritema nodosum il leprosum)
Lasso di tempo: Ad ogni punto di tempo di base
|
Ad ogni punto di tempo di base
|
|
|
Cambiamenti nella neuropatia dal grado di base
Lasso di tempo: 12 settimane
|
12 settimane
|
|
|
Proporzione di soggetti che richiedono farmaci per il salvataggio e tempo di iniziazione dei farmaci per il salvataggio
Lasso di tempo: 12 settimane
|
12 settimane
|
|
|
Quantità totale di trattamento per la reazione di lebbra di tipo 2 somministrata
Lasso di tempo: 12 settimane
|
12 settimane
|
|
|
Resolution of fever to ≤ Grade 1
Lasso di tempo: 12 weeks
|
Proportion of subjects with resolution of fever to ≤ Grade 1 among the subgroup of subjects with fever present at Baseline at Grade 2 or greater. |
12 weeks
|
|
Skin lesion count changes
Lasso di tempo: 12 weeks
|
• Change from Baseline in skin lesion count up to and including Week 12. |
12 weeks
|
|
Change from Baseline of each of the following parameters when present at Baseline at Grade 2 or greater
Lasso di tempo: from baseline to Week 12
|
|
from baseline to Week 12
|
|
Time to resolution
Lasso di tempo: 12 weeks
|
For each individual leprosy type 2 reaction when present at least Grade 1 at Baseline |
12 weeks
|
|
Recurrences
Lasso di tempo: 48 weeks
|
Recurrence is defined as new signs and symptoms consistent with leprosy type 2 reaction. The number of Recurrence episodes requiring treatment. |
48 weeks
|
|
Exposure metrics of dovramilast
Lasso di tempo: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Exposure metrics of the dovramilast metabolite M15
Lasso di tempo: 48 weeks
|
Area under the curve (AUC) |
48 weeks
|
|
Skin lesion count changes
Lasso di tempo: 12 weeks
|
• Proportion of Responders at each post-Baseline timepoint. |
12 weeks
|
|
Skin lesion count changes
Lasso di tempo: 12 weeks
|
Proportion of subjects achieving a reduction of leprosy type 2 reaction skin lesion count from Baseline of 50%, 90% and 100% without Rescue at Week 12. |
12 weeks
|
|
Exposure metrics of dovramilast
Lasso di tempo: 48 weeks
|
Including AUC, Cmax, and Tmax. |
48 weeks
|
|
Exposure metrics of dovramilast
Lasso di tempo: 48 weeks
|
Cmax |
48 weeks
|
|
Exposure metrics of dovramilast
Lasso di tempo: 48 weeks
|
Tmax. |
48 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Quantification of immunological markers in whole blood samples by central laboratory, blinded to patient identification, treatment arm, and study visit
Lasso di tempo: 48 weeks
|
Concentration of inflammatory cytokines |
48 weeks
|
|
Quantification of immunological markers in skin biopsies by central laboratory, blinded to patient identification, treatment arm, and study visit
Lasso di tempo: 48 weeks
|
Leukocyte infiltration of skin lesions by histology |
48 weeks
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Acidi carbossilici
- Composti policiclici
- Piperidine
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Incintadienetrioli
- Ftalimides
- Acidi ftalici
- Acidi, carbociclico
- Piperidoni
- Isoindoli
- Prednisolone
- Talidomide
Altri numeri di identificazione dello studio
- MDGH-DOV-2001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .